DTx Pharma

What DTx Pharma does

DTx Pharma was a US-based biotechnology company founded in 2017 and headquartered in San Diego, specializing in the development of RNA-based therapeutics for neurological disorders. Its core focus was small interfering RNA (siRNA) therapies targeting the genetic drivers of disease, with a particular emphasis on neuropathic pain — a market projected to reach $8.48 billion by 2030 at an 8.1% CAGR, driven by demand for non-opioid treatment alternatives. The company's core technology centered on proprietary siRNA delivery platforms, including novel mechanisms for crossing the blood-brain barrier to enable central nervous system (CNS) gene silencing, and capsid targeting platforms designed to deliver therapeutics to muscle, heart, and CNS tissues. Underlying chemistry and drug development were led by VP Charles Allerson, with VP Bryan Laffitte directing biology.

DTx Pharma operated as a clinical-stage company with no commercial products or revenue-generating operations. Its business model was structured around advancing a pipeline of siRNA candidates toward clinical milestones, supported by venture capital and non-dilutive grant funding. The company raised approximately $113.6 million in total financing across multiple rounds between 2018 and 2021, including a $100 million Series B led by RA Capital Management in March 2021 with participation from Eli Lilly, Cormorant Asset Management, Janus Henderson Investors, Logos Capital, Access Biotechnology, and others. A grant from the National Institute of Neurological Disorders and Stroke (NINDS) in September 2020 provided additional non-dilutive support. Leadership included co-founder and CEO Arthur Suckow, co-founder Adam Pavlicek, COO Denise Bevers, CMO Michael Huang, and CBO Peter Condon.

In July 2023, DTx Pharma was acquired by Novartis AG as part of the pharmaceutical company's strategy to expand its genetic medicine research capabilities in siRNA-based neurological therapeutics. Following the acquisition, DTx Pharma's operations, technology platform, and team were consolidated into Novartis's San Diego genetic medicine research center, joining earlier Novartis genetic medicine assets from the AveXis (2018) acquisition and later integrating with Kate Therapeutics (2024) under Executive Director Bryan Laffitte. The company's xRNA technology and siRNA delivery programs now sit within Novartis's broader portfolio targeting neuromuscular and neurodegenerative diseases.

Name

DTx Pharma

Legal name

DTx Pharma

Website

https://dtxpharma.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

11–50 employees

Short description

DTx Pharma was a San Diego-based biotechnology company developing siRNA therapies for neurological disorders, with proprietary blood-brain barrier delivery technology. Acquired by Novartis in July 2023, its programs are now part of Novartis's genetic medicine research operations.

Ownership category

akta.pro rank

Product category

RNA-based Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industry

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• RNA-based therapeutics
• SiRNA drug development
• Neurological disease therapy
• Blood-brain barrier delivery
• Genetic medicine platform

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain

Core offering

DTx Pharma develops RNA-based therapeutics, with a primary focus on siRNA (small interfering RNA) therapies designed to treat neurological disorders. The company's core technology enables siRNA molecules to cross the blood-brain barrier and target tissues in the central nervous system, muscle, and heart, addressing neuropathic pain and related neurological conditions through gene-silencing mechanisms.

Product overview

DTx Pharma was a US-based biotechnology firm that developed siRNA (small interfering RNA) therapies targeted at neurological disorders including neuropathic pain. The company was acquired by Novartis AG in July 2023 to strengthen Novartis's capabilities in developing siRNA therapies for neurological conditions. Following the acquisition, DTx Pharma's programs and expertise were integrated into Novartis's unified genetic medicine research team in San Diego, combining with existing capabilities from AveXis (2018) and Kate Therapeutics (2024) under Executive Director Bryan Laffitte. The focus areas include siRNA delivery technologies targeting muscle, heart, and CNS tissues, as well as blood-brain barrier crossing mechanisms for treating neurological conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• siRNA Therapies for Neurological Disorders RNA-based therapeutic candidates that use small interfering RNA to silence disease-driving genes in the central nervous system, enabled by DTx's proprietary blood-brain barrier-crossing delivery technology. Targeted at patients with neuropathic pain and related neurological disorders; the development programs and platform were acquired by Novartis AG in July 2023 to be advanced through late-stage development and commercialization.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Alnylam Pharmaceuticals: The leading clinical-stage and commercial siRNA therapeutics company, with multiple approved products (Onpattro, Givlaari, Oxlumo, Amvuttra) and a deep CNS/cardiovascular pipeline. Directly comparable to DTx Pharma on siRNA modality, though at a far more advanced clinical and commercial stage.
• Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics — the closest mechanistic peer to siRNA in the RNA-based drug modality. Has multiple approved products and active programs in neurological disorders, including spinal muscular atrophy (Spinraza), making it a strong direct competitor in CNS-targeted RNA therapeutics.
• Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with proprietary TRiM™ delivery platform targeting multiple tissues including the CNS. Competes directly with DTx Pharma in siRNA delivery innovation for neurological and rare disease indications.
• Silence Therapeutics: Clinical-stage siRNA therapeutics company developing GalNAc-conjugated siRNAs for cardiovascular and hematological diseases. Directly comparable on siRNA platform technology, though with less CNS focus than DTx Pharma.
• Wave Life Sciences: Clinical-stage RNA therapeutics company developing stereopure oligonucleotide therapeutics, with active programs in Huntington's disease and other neurological disorders. Comparable to DTx in neurological RNA therapeutic focus.

Emerging players

• Atalanta Therapeutics: Emerging CNS-focused RNAi therapeutics company developing siRNA therapies for neurodegenerative diseases. Directly comparable to DTx's CNS siRNA focus but at an earlier stage with a narrower therapeutic scope.
• Design Therapeutics: Clinical-stage biotechnology company developing novel small molecules for serious genetic disorders including neurological indications like Friedreich's ataxia. Adjacent peer in the neurological genetic medicine space, though focused on small molecules rather than siRNA.

Broad incumbents

• Novartis AG: Parent company of DTx Pharma and a major global pharmaceutical company with significant neurological and rare disease franchises (including gene therapy via AveXis/Zolgensma). Represents both the validation of DTx's platform and the broader competitive landscape for neurological therapeutics.
• Biogen: Major pharmaceutical company with deep neurological disease franchise (multiple sclerosis, spinal muscular atrophy, Alzheimer's). Represents broad incumbent competition for neurological therapeutics development and commercialization.

Others

• Eli Lilly and Company: Investor in DTx Pharma's $100M Series B (2021) and a major pharmaceutical company with active neurological disease programs including Alzheimer's disease. Connected to DTx both as a prior capital provider and as a broader industry incumbent in neurology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/DTxPharma
• LinkedInlinkedin.com/company/dtxpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DTx Pharma